Trending...
- Update Any Sign Instantly with Santek EZ Sign NFC: Ultra-Slim 4-Color E-Paper Display - 1009
- New Book "Curing Racism" Offers Hopeful Path to Healing America's Deepest Divide
- Hypnotic Hijinks of HypnoMarc Rolls into Sunnyvale for One Night Only
SAN DIEGO, Dec. 4, 2020 /PRNewswire/ -- Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the American Society of Hematology (ASH) for an oral presentation on the preliminary results of a Phase 1b/2 study of AB-205 to prevent or reduce severe organ toxicities associated with high-dose therapy followed by autologous hematopoietic cell transplantation used with curative intent in patients with aggressive systemic lymphoma.
"Our investigators and Angiocrine are honored to be selected by ASH to present at its annual meeting this December," commented Paul Finnegan, MD, Angiocrine CEO. "We look forward to Dr. Michael Scordo's presentation of AB-205's efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication."
Session Name: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence I
Session Date: Saturday, December 5, 2020
Session Time: 7:30 AM - 9:00 AM ET
Presentation Time: 7:45 AM ET
About Severe Regimen-Related Toxicities
High-dose therapy and autologous hematopoietic cell transplantation is considered a standard-of-care method to cure aggressive systemic lymphoma. High dose therapy effectively eradicates cancer cells but also damages healthy tissue, which can lead to severe toxicities. Most affected is the lining of the oral-gastrointestinal (GI) tract. The oral GI tract renews its mucosal lining every 3 to 7 days. Because of the collateral damage from high dose chemotherapy, the oral GI tract loses its ability to renew its lining, leading to inflammation (mucositis) and breakdown, causing nausea, vomiting and diarrhea that are refractory to available medications and require prolonged hospitalization. Severe oral GI toxicities can occur as frequently as 50% and cause profound misery to patients. The rates and severity increase with age and, thus, many older patients are turned away from the curative high dose therapy due to the risks of severe toxicities.
More on The Californer
About AB-205
AB-205 represents a new and unique approach to repairing damaged tissue through advanced cell-and-gene therapy. AB-205 consists of allogeneic (off-the shelf) 'universal' E-CEL® (human engineered cord endothelial) cells. Intravenous AB-205 is given after chemotherapy/radiation (high-dose therapy) conditioning and on the same day as autologous transplant. AB-205's immediate action repairs damaged tissue and thereby prevents (reduces) the extent of breakdown of tissues, which is the root cause of severe toxicities experienced by patients. Reducing or preventing severe toxicities means better quality of life and shorter stay in the hospital—i.e., savings to the healthcare system. AB-205 was recently granted both the Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Angiocrine is actively planning to advance AB-205 into a multi-center single registration Phase 3 trial based on the results of the Phase 1b/2 study.
About Angiocrine Bioscience, Inc.
Angiocrine Bioscience is a clinical-stage biotechnology company developing a radically new way to biologically repair damaged and diseased tissues and organs. Based on its novel and proprietary E-CEL® platform, Angiocrine is developing multiple E-CEL therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system; immune diseases that attack vessels, and ischemic diseases involving soft tissue, central nervous system and the heart.
More on The Californer
For additional information, please contact:
Angiocrine Bioscience, Inc.
John R. Jaskowiak
(877) 784-8496
[email protected]
SOURCE Angiocrine Bioscience, Inc.
Related Links
www.angiocrinebioscience.com
"Our investigators and Angiocrine are honored to be selected by ASH to present at its annual meeting this December," commented Paul Finnegan, MD, Angiocrine CEO. "We look forward to Dr. Michael Scordo's presentation of AB-205's efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication."
Session Name: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence I
Session Date: Saturday, December 5, 2020
Session Time: 7:30 AM - 9:00 AM ET
Presentation Time: 7:45 AM ET
About Severe Regimen-Related Toxicities
High-dose therapy and autologous hematopoietic cell transplantation is considered a standard-of-care method to cure aggressive systemic lymphoma. High dose therapy effectively eradicates cancer cells but also damages healthy tissue, which can lead to severe toxicities. Most affected is the lining of the oral-gastrointestinal (GI) tract. The oral GI tract renews its mucosal lining every 3 to 7 days. Because of the collateral damage from high dose chemotherapy, the oral GI tract loses its ability to renew its lining, leading to inflammation (mucositis) and breakdown, causing nausea, vomiting and diarrhea that are refractory to available medications and require prolonged hospitalization. Severe oral GI toxicities can occur as frequently as 50% and cause profound misery to patients. The rates and severity increase with age and, thus, many older patients are turned away from the curative high dose therapy due to the risks of severe toxicities.
More on The Californer
- Moorpark and Ventura Colleges Named Among Top 200 U.S. Community Colleges Eligible for Aspen Prize
- Carmen Sinata's Raw Demo 'More,' Defying AI-Era Perfection with Real Emotion
- Artwork by a Medea Creek Middle Schooler Selected to Appear in 2026 MWD Calendar
- Oleh Podobied & EDCAPIT Showcased at STARTUPS MIX & PITCH in Silicon Valley (Hacker Dojo)
- Words of Veterans & Veterans Growing America Collaboration
About AB-205
AB-205 represents a new and unique approach to repairing damaged tissue through advanced cell-and-gene therapy. AB-205 consists of allogeneic (off-the shelf) 'universal' E-CEL® (human engineered cord endothelial) cells. Intravenous AB-205 is given after chemotherapy/radiation (high-dose therapy) conditioning and on the same day as autologous transplant. AB-205's immediate action repairs damaged tissue and thereby prevents (reduces) the extent of breakdown of tissues, which is the root cause of severe toxicities experienced by patients. Reducing or preventing severe toxicities means better quality of life and shorter stay in the hospital—i.e., savings to the healthcare system. AB-205 was recently granted both the Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Angiocrine is actively planning to advance AB-205 into a multi-center single registration Phase 3 trial based on the results of the Phase 1b/2 study.
About Angiocrine Bioscience, Inc.
Angiocrine Bioscience is a clinical-stage biotechnology company developing a radically new way to biologically repair damaged and diseased tissues and organs. Based on its novel and proprietary E-CEL® platform, Angiocrine is developing multiple E-CEL therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system; immune diseases that attack vessels, and ischemic diseases involving soft tissue, central nervous system and the heart.
More on The Californer
- Mature Athlete - Want Elite, Web-Based Nutrition and Training Coaching?
- Engaged at Any Age: 73-Year-Old Client Finds True Love Through Elite Asian Matchmaker
- California: CHP hits the Bay Area streets, enforces public safety through its crime suppression teams
- Launch of Professional Private Autopsy Services to Support Families, Professionals, and Researchers
- He Started a New Career at 77; Maybe Not His Last
For additional information, please contact:
Angiocrine Bioscience, Inc.
John R. Jaskowiak
(877) 784-8496
[email protected]
SOURCE Angiocrine Bioscience, Inc.
Related Links
www.angiocrinebioscience.com
Filed Under: Business
0 Comments
Latest on The Californer
- Guillermo X. Márquez Debuts True Crime and Supernatural Comedy Fiction Books
- HEY MEDIA COMPANIES! Want a Big '26? Check out all these great Moneymaking Projects and Promotions!
- Impact LA Responds to Food Crisis in Los Angeles
- THINKWARE Announces Halloween Deals on Popular Dash Cams
- City of Long Beach Facilities and Services Schedule for Election Day
- 20/20 Optometry of Silicon Valley Celebrates 25 Years of Vision Care for the Bay Area!
- PDS Plumbing & Air Honors Veterans with "Free Tune-Up & A Turkey" Giveaway
- PowerMy Introduces Independent Solar Diagnostics Platform to Help Homeowners Save Money
- Hiller's 2025 Flight Simulator Rally Inspires Golf Sim Revolution in Access and Training
- AgeImmune Announces the Launch of ImmuneG.I. — A Doctor-Formulated Herbal Supplement Supporting Gut and Digestive Wellness
- JetZero Commits to Landmark 30-Year Lease Agreement at Long Beach Airport
- Attorney Credits Launches CLE Course: "Religion at Work: A Conflict of Rights"
- Precision Adult Care Unveils Essential Guidelines for Choosing a Senior Home Care Company
- Postmortem Pathology Delivers Expert Private Autopsy Services with Compassion and Precision
- Colorado Families Turn to Private Autopsies for Peace of Mind
- Rachel Farris, CPA Featured in High Net Worth Magazine
- Rachel Farris Joins "Money Tree Investing" Podcast to Explore Puerto Rico's Act 60
- $5.4 Million Growth Acceleration, Fleet Expansion and $1.485 Million Strategic Financing: Multi Ways Holdings (N Y S E: MWG) $MWG
- Delta Capital Group Expands Business Funding Terms Up to 24 Months
- 3 New Members Join The Ventura College Foundation Board, Including Acting Ventura College President